Markets
ADiTx Therapeutics (ADTX)
In a report issued on April 8, Jason Kolbert from Dawson James maintained a Buy rating on ADiTx Therapeutics, with a price target of $14.00. The company’s shares closed last Thursday at $2.56, close to its 52-week low of $1.62.
According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -5.3% and a 37.2% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Citius Pharmaceuticals, Sorrento Therapeutics, and Anavex Life Sciences.
ADiTx Therapeutics has an analyst consensus of Moderate Buy.
Related Keywords
Jason Kolbert , Dawson James , Anavex Life Sciences , Citius Pharmaceuticals , Research Report , Sorrento Therapeutics , Anavex Life , ஜேசன் கோல்பர்ட் , டாசன் ஜேம்ஸ் , ஆராய்ச்சி அறிக்கை , ஸாரெஂடோ சிகிச்சை ,
comparemela.com © 2020. All Rights Reserved.